BKM120 in Cancers With PIK3CA Activating Mutations
This study has been terminated.
(The study has been closed due to lack of accrual)
Sponsor:
Massachusetts General Hospital
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jeffrey Engelman, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01501604
First received: December 27, 2011
Last updated: January 24, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |